Possible role of arginase-1 in concomitant tumor immunity

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Korrer, Michael J ^a,b   Routes, John M ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Hospital of Wisconsin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; E1A ASSOCIATED P300 PROTEIN; E1A PROTEIN; ARGINASE; CD3 ANTIGEN; HYBRID PROTEIN; OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; ENZYME SYNTHESIS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CYTOTOXICITY; ENZYMOLOGY; GENETIC TRANSFECTION; IMMUNITY; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY;

ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, CD3; ARGINASE; CARCINOGENESIS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; IMMUNITY; IMMUNIZATION; MACROPHAGES; MICE, INBRED C57BL; NEOPLASMS; OVALBUMIN; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 84897539031     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091370     Document Type: Article

References (31)

1. Kelekar A, Cole MD (1987) Immortalization by c-myc, H-ras, and Ela oncogenes induces differential cellular gene expression and growth factor responses. Mol Cell Biol 7: 3899-3907.
2. Gallimore PH, McDougall JK, Chen LB (1977) In vitro traits of adenovirus-transformed cell lines and their relevance to tumorigenicity in nude mice. Cell 10: 669-678. (Pubitemid 8102711)
3. Cook JL, Lewis AM Jr, Kirkpatrick CH (1979) Age-related and thymus-dependent rejection of adenovirus 2-transformed cell tumors in the Syrian hamster. Cancer Res 39: 3335-3340. (Pubitemid 9255743)
4. Walker TA, Wilson BA, Lewis AM Jr, Cook JL (1991) E1A oncogene induction of cytolytic susceptibility eliminates sarcoma cell tumorigenicity. Proc Natl Acad Sci USA 88: 6491-6495. (Pubitemid 21914972)
5. Routes JM, Ryan S, Li H, Steinke J, Cook JL (2000) Dissimilar immunogenic-ities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development. Virology 277: 48-57.
6. Cook JL, Krantz CK, Routes BA (1996) Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection. Proc Natl Acad Sci USA 93: 13985-13990. (Pubitemid 26424232)
7. Wang F, Marshall CB, Ikura M (2013) Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell Mol Life Sci 70: 3989-4008.
8. Routes JM, Ryan S, Morris K, Takaki R, Cerwenka A, et al. (2005) Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med 202: 1477-1482. (Pubitemid 41746594)
9. Cook JL, Lewis AM Jr (1984) Differential NK cell and macrophage killing of hamster cells infected with nononcogenic or oncogenic adenovirus. Science 224: 612-615. (Pubitemid 14137531)
10. Cook JL, Walker TA, Lewis AM Jr, Ruley HE, Graham FL, et al. (1986) Expression of the adenovirus E1A oncogene during cell transformation is sufficient to induce susceptibility to lysis by host inflammatory cells. Proc Natl Acad Sci USA 83: 6965-6969. (Pubitemid 16002350)
11. Cook JL, May DL, Wilson BA, Holskin B, Chen MJ, et al. (1989) Role of tumor necrosis factor-alpha in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages. J Immunol 142: 4527-4534. (Pubitemid 19162349)
12. Miura TA, Morris K, Ryan S, Cook JL, Routes JM (2003) Adenovirus E1A, not human papillomavirus E7, sensitizes tumor cells to lysis by macrophages through nitric oxide-and TNF-alpha-dependent mechanisms despite up-regulation of 70-kDa heat shock protein. J Immunol 170: 4119-4126. (Pubitemid 36428175)
13. Routes JM, Ryan S, Clase A, Miura T, Kuhl A, et al. (2000) Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J Immunol 165: 4522-4527.
14. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, et al. (1994) T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27. (Pubitemid 24035278)
15. Barnden MJ, Allison J, Heath WR, Carbone FR (1998) Defective TCR expression in transgenic mice constructed using cDNA-based alpha-and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 76: 34-40. (Pubitemid 28194695)
16. Egan C, Jelsma TN, Howe JA, Bayley ST, Ferguson B, et al. (1988) Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5. Mol Cell Biol 8: 3955-3959.
17. Spiess PJ, Yang JC, Rosenberg SA (1987) In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79: 1067-1075. (Pubitemid 17165278)
18. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, et al. (2000) Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 165: 6047-6055.
19. Loubaki L, Tremblay T, Bazin R (2013) In vivo depletion of leukocytes and platelets following injection of T cell-specific antibodies into mice. J Immunol Methods 393: 38-44.
20. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, et al. (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66: 11238-11246. (Pubitemid 46009952)
21. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, et al. (2000) Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer 85: 182-188. (Pubitemid 30023065)
22. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, et al. (2009) A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 4: e6562.
23. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, et al. (2002) Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol Chem 277: 21123-21129. (Pubitemid 34952247)
24. Rodriguez PC, Quiceno DG, Ochoa AC (2007) L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109: 1568-1573. (Pubitemid 46239590)
25. Taheri F, Ochoa JB, Faghiri Z, Culotta K, Park HJ, et al. (2001) L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin Cancer Res 7: 958s-965s. (Pubitemid 33600951)
26. Stein M, Keshav S, Harris N, Gordon S (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176: 287-292.
27. Rodriguez PC, Hernandez CP, Morrow K, Sierra R, Zabaleta J, et al. (2010) L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. J Immunol 185: 5198-5204.
28. Prati C, Berthelot A, Kantelip B, Wendling D, Demougeot C (2012) Treatment with the arginase inhibitor Nw-hydroxy-nor-L-arginine restores endothelial function in rat adjuvant-induced arthritis. Arthritis Res Ther 14: R130.
29. Iyer RK, Yoo PK, Kern RM, Rozengurt N, Tsoa R, et al. (2002) Mouse model for human arginase deficiency. Mol Cell Biol 22: 4491-4498. (Pubitemid 34620387)
30. Kasten J, Hu C, Bhargava R, Park H, Tai D, et al. (2013) Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse. Mol Genet Metab 110: 222-230.
31. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, et al. (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200: 771-782. (Pubitemid 39299463)